Pharmac prioritised Māori and Pacific patients for access to new diabetes drugs – did they get it right?
- Written by: Lynne Chepulis, Associate Professor Health Sciences, University of Waikato
Getty ImagesThe controversial 2021 decision by the government drug-buying agency Pharmac to prioritise Māori and Pacific patients in its funding of two game-changing new diabetes drugs appears to have paid off.
At the time, Pharmac wanted to restrict funding to those diabetes patients who met certain health criteria. The Diabetes Foundation,...
